The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences announced its earnings results for the third quarter of 2026 and provided a business update.
The company released a press statement outlining its financial performance and recent activities. No further specifics on the results were disclosed in the tweet.
View post on X Loading...
Earlier this month, Solid Biosciences announced plans to present seven posters featuring advances in Duchenne therapies and platform technologies at ESGCT2026, according to a company update. The firm previously secured European Orphan designation for its SGT-212 candidate and reported dosing of five patients in the FALCON trial, as detailed in recent statements. Both announcements highlight ongoing clinical and regulatory progress.